What Treatment Technologies & Insights does

Treatment Technologies & Insights (TTI) is a privately held digital health company founded in 2013 and headquartered in El Segundo, California, that develops the Wave Health Platform — an integrated ecosystem comprising a patient-facing mobile application (Wave Health App, available on iOS and Android across 9 languages and 175 countries), a healthcare provider care portal (Wave Connect), and a proprietary AI-driven analytics engine. The platform collects structured daily patient-reported outcomes (symptoms, medications, mood, sleep, hydration, exercise) across 240+ chronic conditions and uses proprietary algorithms — including Dynamic Time Warping–based symptom cluster analysis — to surface personalized correlations between patient behaviors and condition changes, deliver individualized recommendations, flag emerging adverse events, and generate real-world evidence datasets. Compliance with validated instruments (PRO-CTCAE, PROMIS-29) is built in, and the platform is deployed on AWS infrastructure with HITRUST CSF alignment.

TTI monetizes the platform through a freemium consumer model (free Wave Health app with a modest monthly Wave Pro subscription tier and 30-day trial) layered with enterprise B2B licensing of the full platform — patient app, HCP portal, and analytics — to healthcare systems, cancer centers, specialty pharmacies, payors, and life sciences companies under multi-year contracts. Strategic distribution is anchored by the Walgreens/AllianceRx Walgreens Prime Connected Care Program for oral oncolytic patients, Bayer AG as a study sponsor and UK marketing partner for the prostate cancer version, and clinical collaborations with Fred Hutchinson Cancer Center, Seattle Cancer Care Alliance, Wilmot Cancer Institute, an 8-hospital Spanish consortium, and 7 NHS trusts. Revenue is supplemented by pharma-sponsored real-world evidence generation through studies such as PRO-WAVE1 (Spain), Immunowave (Fred Hutch), and the Wilmot stem cell transplant study.

The company was born from a personal cancer journey — co-founder Ric Grenell's 2013 non-Hodgkin's lymphoma diagnosis led CEO Matt Lashey to manually build the tracking solution that became chemoWave in 2017, rebranded to Wave Health in 2019 when it expanded beyond oncology. TTI has raised approximately $7.5M across disclosed rounds ($1.575M in 2017, $1.5M in 2022 per SEC Form D, and $4.5M in September 2024), is staffed by approximately 17–20 employees across engineering, product, partnerships, and operations, and operates without a parent company or institutional lead investor disclosed.

Name

Treatment Technologies & Insights

Legal name

Treatment Technologies & Insights, LLC

Website

https://tti.care

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Treatment Technologies & Insights (TTI) develops the Wave Health Platform — a patient mobile app, HCP portal, and AI analytics engine for collecting patient-reported outcomes across 240+ chronic conditions. It serves patients, providers, payors, specialty pharmacies, and life sciences companies via freemium consumer subscriptions and B2B enterprise licensing.

Ownership category

akta.pro rank

Product category

Digital Health / Patient-Reported Outcomes Platform

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Health Services (8000), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)

akta.pro secondary industries

DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO), Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK)

Keywords

• Digital health platform
• Patient reported outcomes
• Chronic disease management
• Remote patient monitoring
• Clinical decision support

Headquarters

HQ city

Manhattan Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Freemium App (Wave Health): Free mobile app version with core symptom tracking, daily logging, and basic insights. Premium Wave Pro tier available at a monthly subscription fee offering enhanced reporting and analytics. 30-day free trial offered for Pro version.
2. Enterprise / B2B Solutions: Licensing of Wave Health platform (app, HCP portal, analytics engine) to healthcare organizations, payors, life sciences companies, and specialty pharmacies. Includes custom study configurations, white-label options, and research database access. Revenue derived from multi-year enterprise contracts.
3. Clinical Research & Real-World Data: TTI generates real-world evidence through its platform used in clinical studies conducted with hospital networks, cancer centers, and academic institutions. Studies are supported by pharma partners such as Bayer AG. Data insights are published in peer-reviewed journals.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Treatment Technologies & Insights (TTI) builds the Wave Health digital health platform, an integrated ecosystem comprising a patient-facing mobile app (Wave Health App), a healthcare provider web portal (Wave Connect), and a proprietary AI-driven analytics engine. The platform collects electronic patient-reported outcomes (ePROs) and daily health data across 240+ chronic conditions, then generates personalized, actionable insights to support patients, providers, payors, and life sciences organizations.

Product overview

Treatment Technologies & Insights (TTI) offers the Wave Health Platform, a unified digital health ecosystem comprising three integrated components: the Wave Health patient mobile app (for iOS and Android), the Wave Connect care portal for healthcare providers, and a proprietary AI-driven analytics engine. The platform collects comprehensive patient-reported outcomes and daily health data (symptoms, medications, mood, sleep, activity) and generates personalized, actionable insights. TTI's product portfolio also includes specialized research platforms such as the TRIO041 Portal and the RenoTace clinical trial app, and has been used to conduct multiple real-world evidence studies including the PRO-WAVE1 study, the Immunowave study (Fred Hutchinson Cancer Center), and UK NHS feasibility studies. TTI's original 2017 product, chemoWave, was rebranded and expanded into Wave Health in 2019.

Differentiator

Problem solved

Functional benefit

Brands

• Wave Health: Digital health platform comprising a patient app, analytics engine, and HCP portal that collects patient-reported outcomes to generate actionable insights for chronic condition management.
• Wave Health App
• Wave Connect Portal
• chemoWave

Quantifiable outcome

• 93.3% ePRO patient compliance in multicenter study (vs. typical <50% benchmarks)
• +7 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and key.

• Health Innovation Oxford & Thames ValleycoreStrategic or Co-development Partner · 18 November 2024UK feasibility study assessing Wave Health for prostate cancer management with 15 end-users from 7 NHS trusts. Funded by Bayer Plc. Used Lean Assessment Process methodology to assess barriers and acceptance for NHS adoption. Results indicated platform could add substantial value to current PC care pathways.
• Bayer AGkeyGTM or Marketing Partner · 25 January 2024Bayer AG financially supported the PRO-WAVE1 Spain multicenter study and serves as marketing agent for the prostate cancer version of Wave Health in the UK. Bayer is not responsible for product content or function. TTI retains full control of product development and content.
• Fred Hutchinson Cancer Center / University of WashingtoncoreStrategic or Co-development Partner · 31 May 2023Collaborative Immunowave study using Wave Health ePRO platform to assess symptoms and quality of life in patients with prior or ongoing immune checkpoint inhibitor therapy. Two abstracts accepted at ASCO 2023. Study demonstrated feasibility of ePRO collection in ICI-treated patients with 90% of participants willing to recommend the app.
• Walgreens / AllianceRx Walgreens PrimekeyChannel Partner/ Reseller/ Distributor · 4 May 2022Connected Care Program: TTI provides its AI-driven patient app and Wave Connect pharmacist care portal for the specialty pharmacy's patient monitoring program. Pharmacists enroll patients, review synthesized reports before interactions, and conduct informed consults. Connected Care Program is PRO algorithm-driven with all PROs and counseling documented in patient profiles.
• Seattle Cancer Care Alliance (SCCA)coreStrategic or Co-development Partner · 26 October 2021Pilot study at SCCA using Wave Health app to examine immunotherapy symptoms and side effects in approximately 50 patients over 3 months. Patients use PRO-CTCAE instruments and PROMIS-29 questionnaires to generate real-world evidence on patient experiences with immunotherapy.
• Spanish Hospital Consortium (8 hospitals)coreStrategic or Co-development PartnerPRO-WAVE1 multicenter study conducted across 8 Spanish hospitals: Hospital Universitario Marques de Valdecilla, Complejo Hospitalario de Navarra, Oncologico de Donostia, Fundacio Puigvert Barcelona, Hospital Universitario La Paz, Hospital Universitario Virgen del Rocio, Hospital de la Sta. Creu i Sant Pau, and Hospital Universitarios Cruces. Demonstrated 93.3% ePRO compliance and 98% HCP usefulness.
• Wilmot Cancer Institute (University of Rochester Medical Center)coreStrategic or Co-development PartnerFeasibility study assessing Wave Health for stem cell transplant patients to self-monitor for chronic Graft-versus-Host Disease (cGVHD). 15 patients engaged over 4 weeks with 88% weekly app usage and 89% usability rating. Selected for oral presentation at ONS Congress 2024.

Scale indicators6 records

Recent moves6 records

Direct peers

• Carevive Systems: Carevive Systems provides an oncology-focused digital platform for electronic patient-reported outcomes (ePRO), remote symptom monitoring, and care management. It is the closest direct competitor to TTI, targeting the same oncology provider, pharma, and patient populations with overlapping ePRO, HCP portal, and risk triage capabilities.
• Noona (Elekta): Noona, acquired by Elekta, is an oncology-specific patient outcomes platform that captures patient-reported outcomes and supports care teams in cancer clinics. It is a direct peer to TTI's Wave Health and Wave Connect for oncology symptom monitoring and PRO data collection.
• Kaiku Health: Kaiku Health (now part of Egetis/soon-to-be renamed) provides a digital therapeutics platform for cancer symptom monitoring and patient-reported outcomes across multiple European cancer centers. It is a direct peer with overlapping ePRO, AI-driven symptom analytics, and oncology clinical study capabilities.
• Castor EDC: Castor EDC offers an electronic data capture platform with a strong ePRO module used in clinical trials across therapeutic areas including oncology. Comparable to TTI's PRO-WAVE1 research database offering, with overlap in clinical study configurations and validated PRO instrument support.
• Medable: Medable provides a decentralized clinical trial platform that includes ePRO, eConsent, and remote patient engagement. Overlaps with TTI's clinical research and real-world evidence offering, particularly for pharma-sponsored decentralized oncology trials.
• Outcomes4Me: Outcomes4Me is a cancer patient empowerment app that uses AI to deliver personalized treatment insights, clinical trial matching, and symptom tracking. Closely comparable to Wave Health's patient-facing mobile experience and oncology focus.

Broad incumbents

• Tempus Labs: Tempus is a large-scale oncology AI and precision medicine platform that combines molecular data, clinical data, and patient-reported outcomes. It is a broader incumbent in oncology RWE with overlapping life sciences, pharma, and provider customers.
• Flatiron Health: Flatiron Health (acquired by Roche) is a market-leading oncology real-world evidence and EHR data platform serving providers, payors, and life sciences. Comparable to TTI's life sciences and RWE offerings but at significantly greater scale and with deeper EHR integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/tti_care
• Facebookfacebook.com/chemowave
• LinkedInlinkedin.com/company/treatment-technologies-insights
• Instagraminstagram.com/tti.care

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Treatment Technologies & Insights